Spire Healthcare Group delivered consistent financial results in the second half of 2025, with revenue rising 6.3% year-on-year and adjusted EBITDA margin holding at 21.4%. The UK-based private healthcare provider continues to benefit from strong outpatient volumes and operational efficiency.
- Revenue increased 6.3% YoY to £287.2 million in H2 2025
- Adjusted EBITDA margin held steady at 21.4%
- Outpatient procedures rose 7.8% YoY
- Capital expenditure: £29.4 million, focused on digital and facility upgrades
- Full-year 2025 guidance reaffirmed: 5.5%-6.5% revenue growth, 21.0%-21.5% EBITDA margin
- Final dividend of 7.0p per share, total annual payout 13.5p
Spire Healthcare Group reported stronger-than-expected performance in the second half of 2025, with revenue reaching £287.2 million, up 6.3% compared to the same period in 2024. The improvement was driven by a 7.8% increase in outpatient procedures and sustained demand for private elective care across its network of 26 facilities in the UK. The company maintained an adjusted EBITDA margin of 21.4%, reflecting disciplined cost management and improved asset utilization. The results underscore the resilience of the private healthcare sector in the UK, even amid ongoing pressures on public health spending. Spire reported a 5.1% year-on-year increase in average revenue per patient, attributed to higher utilization of premium services and expanded contract offerings with private insurers. Capital expenditure for the period totaled £29.4 million, primarily directed toward digital infrastructure upgrades and facility modernization at sites in London, Manchester, and Glasgow. The company reaffirmed its full-year 2025 guidance, forecasting revenue growth between 5.5% and 6.5% and an adjusted EBITDA margin in the 21.0% to 21.5% range. Shareholders noted that the company’s return on invested capital reached 11.7% in H2, up from 10.9% in H1, signaling improving capital efficiency. Spire also announced a final dividend of 7.0p per share, bringing the total annual payout to 13.5p. The stock, trading under the ticker SPRI.L, showed modest gains following the release, outperforming the broader UKX index by 1.2 percentage points over the next two trading sessions. Investors appear to view the results as a confirmation of Spire’s ability to deliver predictable growth in a competitive healthcare landscape.